Approval Date: Feb 2022
A first-time generic for Farxiga, a medication used to treat type 2 diabetes, as well as adults with certain kinds of heart failure chronic kidney disease.
Approval Date: Feb 2022
A first-time generic of Revex, this drug is indicated for the complete or partial reversal of opioid drug effects, including respiratory depressions from natural or synthetic opioids, and for the management of opioid overdose
Approval Date: Feb 2022
Indicated for the treatment of chronic angina, a type of chest pain caused by reduced blood flow to the heart.
Approval Date: Feb 2022
A peppermint-flavored solution indicated for the treatment of hypertension and angina. Amlodipine is available as a generic in oral tablets.
Approval Date: Feb 2022
Indicated for the treatment of spasticity resulting from multiple sclerosis, as well as in patients with spinal cord injuries or diseases.
Approval Date: Jan 2022
Indicated for the treatment of Hepatitis C genotypes 1-4 in patients without cirrhosis, or with compensated cirrhosis as part of a combination antiviral treatment regimen.
Approval Date: Jan 2022
Indicated for the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.
Approval Date: Dec 2021
Indicated to reduce the risk of HIV-1 infection
Approval Date: Dec 2021
Indicated to improve glycemic control for type 1 and 2 diabetes
Approval Date: Dec 2021
The 7th biosimilar approved for adalimumab. For the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s Disease, ulcerative colitis, and plaque psoriasis
Approval Date: Nov 2021
Indicated for the treatment of seizures, and for the preventive treatment of migraine
Approval Date: Nov 2021
Indicated for the treatment of opioid-induced constipation
Approval Date: Oct 2021
Indicated for the emergency treatment of known or suspected opioid overdose
Approval Date: Oct 2021
A combination opioid agonist and NSAID indicated for the management of acute pain severe enough to require an opioid and for which alternative treatments are inadequate
Approval Date: Oct 2021
A biosimilar to Humira, this drug is now officially interchangeable with Humira for the treatment of moderate-to-severe rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, moderate-to-severe Crohn’s disease, moderate-to-severe ulcerative colitis, and moderate-to-severe chronic plaque psoriasis
